Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Jiangsu Deyuan Pharmaceutical Co EV-to-FCF?
Jiangsu Deyuan Pharmaceutical CoBJSE:920735 97 EV-to-FCF is 22.08 as of Sep. 02, 2026, which is 16% below its 10-year median of 26.23. GuruFocus rates BJSE:920735 with a GF Score™ of 97/100 and a GF Value™ of ¥29.61 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 566 Drug Manufacturers companies, Jiangsu Deyuan Pharmaceutical Co ranks worse than 53% on this metric.
The historical rank and industry rank for Jiangsu Deyuan Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
BJSE:920735'
s EV-to-FCF Range Over the Past 10 Years
Min: 4.67 Med: 26.23 Max: 61.83
Current: 21.88
During the past 13 years, the highest EV-to-FCF of Jiangsu Deyuan Pharmaceutical Co was 61.83. The lowest was 4.67. And the median was 26.23.
BJSE:920735's EV-to-FCF is ranked worse than 53% of 566
companies
in the Drug Manufacturers industry
Industry Median: 19.82
vs BJSE:920735: 21.88
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jiangsu Deyuan Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Jiangsu Deyuan Pharmaceutical Co's share price for today is ¥26.66.
Jiangsu Deyuan Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2.076.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Jiangsu Deyuan Pharmaceutical Co EV-to-FCF Related Terms
Jiangsu Deyuan Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Deyuan Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Deyuan Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Deyuan Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Jiangsu Deyuan Pharmaceutical Co's EV-to-FCF falls into.
Jiangsu Deyuan Pharmaceutical Co's current Enterprise Value is ¥2,982 Mil.
Jiangsu Deyuan Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥135 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) has a EV-to-FCF of 22.08 as of Sep. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Jiangsu Deyuan Pharmaceutical Co and its competitors. This is 16% below median its historical median of 26.23. Over the past decade, Jiangsu Deyuan Pharmaceutical Co's EV-to-FCF has ranged from 4.67 to 61.83. According to the industry distribution chart, Jiangsu Deyuan Pharmaceutical Co ranks #300 out of 566 companies in the Drug Manufacturers industry, placing it in the top 53%.
Is Jiangsu Deyuan Pharmaceutical Co's EV-to-FCF too high?
Jiangsu Deyuan Pharmaceutical Co's current EV-to-FCF of 22.08 is 16% below median its 10-year median of 26.23. Over the past 10 years, this metric has ranged from a low of 4.67 to a high of 61.83. The Drug Manufacturers industry median EV-to-FCF is 19.82. Jiangsu Deyuan Pharmaceutical Co's value of 22.08 is 11.4% above this industry median. Based on the distribution chart, Jiangsu Deyuan Pharmaceutical Co ranks #300 out of 566 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Jiangsu Deyuan Pharmaceutical Co has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Deyuan Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jiangsu Deyuan Pharmaceutical Co ranks #300 out of 566 companies for EV-to-FCF. This places Jiangsu Deyuan Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 19.82. Jiangsu Deyuan Pharmaceutical Co's value of 22.08 is 11.4% above this benchmark. Historically, Jiangsu Deyuan Pharmaceutical Co's own EV-to-FCF has ranged from 4.67 to 61.83 over the past decade. While the company's 10-year median is 26.23 vs. the industry median of 19.82, Jiangsu Deyuan Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.82, based on 566 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Deyuan Pharmaceutical Co's current EV-to-FCF of 22.08 is 11.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Jiangsu Deyuan Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Deyuan Pharmaceutical Co's current EV-to-FCF is 22.08, which is 16% below median its own 10-year median of 26.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Deyuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥29.61, compared to a current price of ¥26.66 — trading 10% below its estimated fair value. The current EV-to-FCF is 22.08, which is 16% below median its 10-year median of 26.23 and 11.4% above the Drug Manufacturers industry median of 19.82. Jiangsu Deyuan Pharmaceutical Co's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Jiangsu Deyuan Pharmaceutical Co (BJSE:920735), the current EV-to-FCF is 22.08 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Deyuan Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥26.66 is trading 10% below its estimated GF Value™ of ¥29.61.
GuruFocus considers Jiangsu Deyuan Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for BJSE:920735:
EV-to-FCF: 22.08 (16% below median its 10-year median of 26.23)
GF Value™: ¥29.61 vs. price of ¥26.66 (10% below fair value)
Industry Position: 11.4% above the Drug Manufacturers median (#300 of 566)
No single metric tells the full story. See the BJSE:920735 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920735 has been successfully added to your 
